Univariate and multivariate analyses for csCMVi
| Characteristics . | Univariate analysis . | Multivariate analysis . | |
|---|---|---|---|
| P value . | HR (95% CI) . | P value . | |
| Letermovir prophylaxis | <.001 | 0.488 (0.405-0.589) | <.001 |
| Patient age at HSCT, >50 y | .26 | ||
| Diagnosis | .82 | ||
| Disease risk high | .021 | 0.884 (0.790-0.990) | .033 |
| PS > 1 | <.001 | 0.617 (0.498-0.764) | <.001 |
| HCT-CI > 2 | .51 | ||
| Donor CMV IgG | .15 | ||
| BMT | .024 | 0.955 (0.827-1.10) | .54 |
| PBSCT | 1.0 | ||
| CBT | .011 | 1.08 (0.902-1.30) | .40 |
| HLA-mismatched donor | <.001 | 1.41 (1.23-1.62) | <.001 |
| Female donor to male recipient | .61 | ||
| Unrelated donor | .070 | ||
| Number of HSCT > 1 | .34 | ||
| MAC | .13 | ||
| ATG use | .001 | 1.29 (1.08-1.54) | .005 |
| Characteristics . | Univariate analysis . | Multivariate analysis . | |
|---|---|---|---|
| P value . | HR (95% CI) . | P value . | |
| Letermovir prophylaxis | <.001 | 0.488 (0.405-0.589) | <.001 |
| Patient age at HSCT, >50 y | .26 | ||
| Diagnosis | .82 | ||
| Disease risk high | .021 | 0.884 (0.790-0.990) | .033 |
| PS > 1 | <.001 | 0.617 (0.498-0.764) | <.001 |
| HCT-CI > 2 | .51 | ||
| Donor CMV IgG | .15 | ||
| BMT | .024 | 0.955 (0.827-1.10) | .54 |
| PBSCT | 1.0 | ||
| CBT | .011 | 1.08 (0.902-1.30) | .40 |
| HLA-mismatched donor | <.001 | 1.41 (1.23-1.62) | <.001 |
| Female donor to male recipient | .61 | ||
| Unrelated donor | .070 | ||
| Number of HSCT > 1 | .34 | ||
| MAC | .13 | ||
| ATG use | .001 | 1.29 (1.08-1.54) | .005 |
BMT, bone marrow transplantation; CBT, cord blood transplantation; HCT-CI, hematopoietic cell transplantation-specific comorbidity index; HR, hazard ratio; MAC, myeloablative conditioning; PBSCT, peripheral blood stem cell transplantation.